Rachel Phillips1, Mihir Gandhi2, Yin Bun Cheung3, Michael P Findlay4, Khin Maung Win5, Hoang Hoa Hai6, Jin Mo Yang7, Rolley Rey Lobo8, Khee Chee Soo9, Pierce K H Chow10. 1. Biostatistics Department, Singapore Clinical Research Institute, 31 Biopolis Way, Nanos #0201, Singapore 138669; Centre for Quantitative Medicine, Office of Clinical Sciences, Academia, 20 College Road, Singapore Duke-NUS Graduate Medical School, Singapore. Electronic address: rachel.phillips@scri.edu.sg. 2. Biostatistics Department, Singapore Clinical Research Institute, 31 Biopolis Way, Nanos #0201, Singapore 138669; Centre for Quantitative Medicine, Office of Clinical Sciences, Academia, 20 College Road, Singapore Duke-NUS Graduate Medical School, Singapore; Department of International Health, School of Medicine, Lääkärinkatu 1, 33014 University of Tampere, Tampere, Finland. 3. Biostatistics Department, Singapore Clinical Research Institute, 31 Biopolis Way, Nanos #0201, Singapore 138669. 4. Discipline of Oncology, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand. 5. Department of Hepatology, Yangon GI and Liver Centre, 91-193, 30th Street (Upper Block), Pabedan Township, Yangon 11141, Myanmar. 6. Training and Research Department, Cho Ray Hospital, 201B Nguyen Chi Thanh Street, District 5, Ho Chi Minh City, Vietnam. 7. Department of Internal Medicine, Catholic University Medical College, 93-6 Chi-dong, Paldal-ku, Suwon 442-720, Korea. 8. Department of Liver and Pancreatic-Biliary Surgery, Davao Doctors Hospital, Quirino Street, Davao City, The Philippines. 9. Centre for Quantitative Medicine, Office of Clinical Sciences, Academia, 20 College Road, Singapore Duke-NUS Graduate Medical School, Singapore; Department of Surgical Oncology, National Cancer Center Singapore, 11 Hospital Drive, Singapore 169610. 10. Centre for Quantitative Medicine, Office of Clinical Sciences, Academia, 20 College Road, Singapore Duke-NUS Graduate Medical School, Singapore; Department of Surgical Oncology, National Cancer Center Singapore, 11 Hospital Drive, Singapore 169610; Deparment Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Outram Road, Singapore 169608.
Abstract
OBJECTIVES: To examine the performance of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) global health status/quality of life (QoL) scale and two summary scores to detect changes in the QoL profile over time, according to changes in the individual scales. STUDY DESIGN AND SETTING: Data came from 167 clinical trial patients with unresectable (advanced) hepatocellular carcinoma. The global health status/QoL scale of the questionnaire contained two items: overall health and overall QoL. Nordin and Hinz proposed summary scores for the questionnaire. A mixed-effect model was fitted to estimate trends in scores over time. RESULTS: Predominantly the individual scale scores declined over time; however, the global health status/QoL score was stable [rate of change = -0.3 per month; 95% confidence interval (CI): -1.2, 0.6]. Nordin's summary score, which gave equal weight to the 15 questionnaire scales, and Hinz's summary score, which gave equal weight to the 30 questionnaire items, showed a statistically significant decline over time, 3.4 (95% CI: -4.5, -2.4) and 4.2 (95% CI: -5.3, -3.0) points per month, respectively. CONCLUSION: In contrast to the global health status/QoL scale, the summary scores proposed by Nordin and Hinz detected changes in subjects' QoL profile described by the EORTC QLQ-C30 individual scales.
OBJECTIVES: To examine the performance of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) global health status/quality of life (QoL) scale and two summary scores to detect changes in the QoL profile over time, according to changes in the individual scales. STUDY DESIGN AND SETTING: Data came from 167 clinical trial patients with unresectable (advanced) hepatocellular carcinoma. The global health status/QoL scale of the questionnaire contained two items: overall health and overall QoL. Nordin and Hinz proposed summary scores for the questionnaire. A mixed-effect model was fitted to estimate trends in scores over time. RESULTS: Predominantly the individual scale scores declined over time; however, the global health status/QoL score was stable [rate of change = -0.3 per month; 95% confidence interval (CI): -1.2, 0.6]. Nordin's summary score, which gave equal weight to the 15 questionnaire scales, and Hinz's summary score, which gave equal weight to the 30 questionnaire items, showed a statistically significant decline over time, 3.4 (95% CI: -4.5, -2.4) and 4.2 (95% CI: -5.3, -3.0) points per month, respectively. CONCLUSION: In contrast to the global health status/QoL scale, the summary scores proposed by Nordin and Hinz detected changes in subjects' QoL profile described by the EORTC QLQ-C30 individual scales.
Authors: Andreas Hinz; Joachim Weis; Hermann Faller; Elmar Brähler; Martin Härter; Monika Keller; Holger Schulz; Karl Wegscheider; Uwe Koch; Kristina Geue; Heide Götze; Anja Mehnert Journal: Support Care Cancer Date: 2018-04-26 Impact factor: 3.603
Authors: Douglas W Blayney; Ramon Mohanlal; Hryhoriy Adamchuk; Dmitry Valikovich Kirtbaya; Michael Chen; Lihua Du; Stephan Ogenstad; Greg Ginn; Lan Huang; Qingyuan Zhang Journal: JAMA Netw Open Date: 2022-01-04
Authors: Antonio Di Meglio; Julie Havas; Arnauld S Gbenou; Elise Martin; Mayssam El-Mouhebb; Barbara Pistilli; Gwenn Menvielle; Agnes Dumas; Sibille Everhard; Anne-Laure Martin; Paul H Cottu; Florence Lerebours; Charles Coutant; Anne Lesur; Olivier Tredan; Patrick Soulie; Laurence Vanlemmens; Florence Joly; Suzette Delaloge; Patricia A Ganz; Fabrice André; Ann H Partridge; Lee W Jones; Stefan Michiels; Ines Vaz-Luis Journal: J Clin Oncol Date: 2022-04-21 Impact factor: 50.717